Advances in the treatment of chronic wounds: A patent review

Expert Opinion on Therapeutic Patents

Volumn 25, Issue 8, 2015, Pages 931-937

  Van Koppen, Chris J ^a   Hartmann, Rolf W ^a,b,c  

^a ElexoPharm GmbH   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Bone marrow derived mesenchymal stem cells; Connexin43; CYP11B1; Decubitus; Diabetes; Elastase; Growth factors; Matrix metalloproteinases; Prolyl 4 hydroxylase; Wound healing

Indexed keywords

CONNEXIN 43 INHIBITOR; CYP11B1 INHIBITOR; ELASTASE INHIBITOR; ENZYME INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; OXYGENASE INHIBITOR; PROLYL 4 HYDROXYLASE INHIBITOR; PROTEIN INHIBITOR; RECOMBINANT GROWTH FACTOR; UNCLASSIFIED DRUG; BIOLOGICAL FACTOR;

BONE MARROW DERIVED MESENCHYMAL STEM CELL; CHRONIC WOUND; HUMAN; REVIEW; WOUND HEALING; ANIMAL; CHRONIC DISEASE; DRUG EFFECTS; PATENT; PATHOLOGY; QUALITY OF LIFE; WOUNDS AND INJURIES;

ANIMALS; BIOLOGICAL FACTORS; CHRONIC DISEASE; HUMANS; PATENTS AS TOPIC; QUALITY OF LIFE; WOUND HEALING; WOUNDS AND INJURIES;

EID: 84937214923     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2015.1045879     Document Type: Review

References (63)

1. Richmond NA, Lamel SA, Davidson JM, et al. US-National institutes of Healthfunded research for cutaneous wounds in 2012. Wound Repair Reg 2013;21:789-92
2. Heublein H, Bader A, Giri S. Preclinical and clinical evidence for stem cell therapies as treatment for diabetic wounds. Drug Discov Today 2015. [Epub ahead of print]
3. Sun BK, Siprashvilli Z, Khavari PA. Advances in skin grafting and treatment of cutaneous wounds. Science 2014;346:941-5
4. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005;366:1736-43
5. Schreml S, Szeimies RM, Prantl L, et al. Wound healing in the 21st century. J Am Acad Dermatol 2010;63:866-81
6. Tomic-Canic M, Brem H, Samuels HH. De novo synthesis of glucocorticoids in the epidermis and its uses and applications. US 8, 802, 660 B2; 2014
7. Slominski A, Zbytek B, Nikolakis G, et al. Steroidogenesis in the skin: implication for local immune functions. J Steroid Biochem Mol Biol 2013;137:107-23
8. Slominski AT, Manna PR, Tuckey RC. Cutaneous glucocorticosteroidogenesis: securing local homeostasis and the skin integrity. Exp Dermatol 2014;23:369-74
9. Vukelic S, Stojadinovic O, Pastar I, et al. Cortisol synthesis in epidermis is induced by IL-1 and tissue injury. J Biol Chem 2011;286:10265-75
10. Wikramanayaka TC, Stojadinovic O, Tomic-Canic M. Epidermal differentiation in barrier maintenance and wound healing. Adv Wound Care 2014;3:272-80
11. Gould L, Abadir P, Brem H, et al. Chronic wound repair and healing in older adults: current status and future research. Wound Rep Regen 2015;63(3):427-38
12. Pastar I, Stojadinovic O, Yin NC, et al. Epithelialization in wound healing: A comprehensive review. Adv Wound Care 2014;3:445-64
13. Santoro MM, Gaudino G. Cellular and molecular facets of keratinocyte reepithelization during wound healing. Exp Cell Res 2005;304:274-86
14. Carty SM, Cochrane CA, Clegg PD, Percival SL. The role of endogenous enzymes in chronic wounds: A focus on the implications of aberrant levels of both host and bacterial proteases in wound healing. Wound Rep Reg 2012;20:125-36
15. Churko JM, Laird DW. Gap junction remodeling in skin repair following wounding and disease. Physiology 2013;28:190-8
16. Becker DL, Thrasivoulou C, Philips ARJ. Connexins in wound healing: perspectives in diabetic patients. Biochim Biophys Acta 2012;1818:2068-75
17. Stojadinovic O, Gordon KA, Lebrun E, Tomic-Canic M. Stress-induced hormones cortisol and epinephrine impair wound epithelization. Adv Wound Care 2012;1:29-35
18. Yao J, Yang W, Liu Y, et al. Dexamethasone inhibits TGF-2-induced migration of human lens epithelial cells: implications for posterior capsule opacification prevention. Mol Med Reports 2012;5:1509-13
19. Shikatani EA, Trifonova A, Mandel ER, et al. Inhibition of proliferation, migration and proteolysis contribute to corticosterone-mediated inhibition of angiogenesis. PLoS ONE 2012;7:e46625
20. Tiganescu A, Tahrani AA, Morgan SA, et al. 11b-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects. J Clin Invest 2013;123:3051-60
21. Wang AS, Armstrong EJ, Armstrong AW. Corticosteroids and wound healing: clinical considerations in the perioperative period. Am J Surg 2013;206:410-17
22. Hille UE, Zimmer C, Haupenthal J, Hartmann RW. Optimization of the first selective steroid-11b-hydroxylase (CYP11B1) inhibitors for the treatment of cortisol dependent diseases. ACS Med Chem. Lett 2011;2:559-64
23. Emmerich J, Hu Q, Hanke N, Hartmann RW. Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)-pyridine type. J Med Chem 2013;56:6022-32
24. Zhu W, Hu Q, Hanke N, et al. Potent 11-hydroxylase inhibitors with inverse metabolic stability in human plasma and hepatic S9 fractions to promote wound healing. J Med Chem 2014;57:7811-17
25. Hartmann R, Hille U, Hu Q, et al. Selective Cyp11b1 inhibitors for the treatment of cortisol dependent diseases. WO2012052540 A1; 2012
26. Bionetworks GmbH. Wilckens T. 11b-Hydroxysteroid dehydrogenases. WO 2006097337 A2; 2006
27. Amgen Inc. Biovitrum Ab. Substituted azole aromatic heterocycles as inhibitors of 11b-HSD-1. WO2008011453 A2; 2008
28. Amgen Inc. Biovitrum. Ab. Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1. CA2630718 A1; 2007
29. Vitae Pharmaceuticals Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1. WO2010091067 A2; 2010
30. Davidson JM. First-class delivery: getting growth factors to their destination. J Invest Dermatol 2008;128:1360-2
31. Judith R, Nithya M, Rose C, et al. Application of a PDGF-containing novel gel for ctaneous wound healing. Life Sci 2010;87:1-8
32. Cheng B, Liu HW, Fu XB, et al. Recombinant human platelet-derived growth factor enhanced dermal wound healing by a pathway involving ERK and c-fos in diabetic rats. J Dermatol Sci 2007;45:193-201
33. Sun W, Lin H, Xie H, et al. Collagen membranes loaded with collagen-binding human PDGF-BB accelerate wound healing in a rabbit dermal ischemic ulcer model. Growth Fact 2007;25:309-18
34. Vegenics Pty Ltd. Methods of stimulating wound healing by administration of vascular endothelial growth factor D (VEGF-D). US8227410 B2; 2012
35. Gene Signal International SA. Novel peptides for wound healing. US20110306545 A1; 2011
36. Ranbaxy Laboratories Ltd. Matrix metalloproteinase inhibitors. US8846910 B2; 2014
37. Janssen Pharmaceutica NV. Thiazol derivatives as pro-matrix metalloproteinase inhibitors. WO2012162468 A1; 2012
38. Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins. US8013125 B2. 2011
39. Amgen. Polypeptides that bind tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods. US20140228540 A1; 2014
40. Kimberly-Clark Worldwide, Inc. Metalloproteinase inhibitors for wound healing. US7186693 B2; 2007
41. Hong WX, Hu MS, Esquivel M, et al. The role of hypoxia-inducible factor in wound healing. Adv Wound Care 2014;3:390-9
42. Bayer Intellectual Property GmbH. Substituted dihydropyrazolones and use thereof as HIF-prolyl-4-hydroxylase inhibitors. US8524699 B2; 2013
43. Amgen. Diazaquinolones that inhibit prolyl hydroxylase activity. US8097620 B2; 2012
44. GlaxoSmithKline Llc. Prolyl hydroxylase inhibitors. WO2010059552 A1; 2010
45. Janssen Pharmaceutica N. V. Benzoimidazole glycinamides as prolyl hydroxylase inhibitors. WO2009134754 A1; 2009
46. Ruthenborg RJ, Ban J-J, Wazir A, et al. Regulation of wound healing and fibrosis by hypoxia and hypoxia-inducible factor-1. Mol Cells 2014;37:637-43
47. Maxson S, Lopez EA, Yoo D, et al. Concise review: role of mesenchymal stem cells in wound repair. Stem Cells Trans Med 2012;1:142-9
48. Chen JS, Wong VW, Gurtner GC. Therapeutic potential of bone marrowderived mesenchymal stem cells for cutaneous wound healing. Front Immun 2012;3:192
49. Nuschke A. Activity of mesenchymal stem cells in therapies for chronic skin wound healing. Organesis 2014;10:29-37
50. Cryo-Cell International, Inc. Cell therapy to improve wound healing and related compositions and methods. EP2553089 A1; 2013
51. Mesoblast International Sarl. Mesenchymal stem cells and uses therefor. US 2011/0318314 A1; 2011
52. US Department of Veterans Affairs, University of Utah Research Foundation. Stem cell, precursor cell, or target cellbased treatment of multi-organ failure and renal dysfunction. US20140086886 A1; 2014
53. Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells and isolated cell populations generated thereby. US20140023623 A1; 2014
54. Barros SC, Martins JA, Marcos JC, Cavaco-Paulo A. Characterization of potential elastase inhibitor-peptides regulated by a molecular switch for wound dressings applications. Enzym Micro Tec 2012;50:107-14
55. Carty SM, Percival SL. Proteases and delayed wound healing. Adv Wound Care 2013;2:438-47
56. Delano FA, Schonbein GW. Methods to accelerate tissue and wound healing rates and reduce swelling and scar formation. WO2011038417 A2; 2011
57. Essler A, Nisbet L. Promotion of wound healing. WO20060145182 A2; 2006
58. Lezdey J, Lezdey DB. Topical wound therapeutic compositions. US6262020 B1; 2001
59. Ormondo S, Chou C-Y, Goold L, et al. Regulation of connexin43 gap junction protein triggers vascular recovery and healing in human ocular persistent epithelial defect wounds. J Membr Biol 2012;245:381-8
60. Ongstad EL, O'Quinn MP, Ghatnekar G. A connexin43 mimetic peptide promotes regenerative healing and improves mechanical properties in skin and heart. Adv Wound Care 2013;2:55-62
61. Ghatnekar GS, Grek CL, Armstrong DG, et al. The effect of a connexin43. based peptide on the healing of chronic venous leg ulcers: A multicenter, randomized trial. J Invest Dermatol 2015;135:289-98. The first clinical data on Cx43 inhibitor to promote wound healing in chronic venous ulcer.
62. Gourdie R, Ghatnekar G, Jourdan J. Compositions and methods for promoting wound healing and tissue regeneration. EP2377546 A2; 2011
63. Coda Therapeutics Inc. Anti-connexin compounds targeted to connexins and methods of use thereof. US8815819; 2014